458 related articles for article (PubMed ID: 23954262)
1. Current therapy of myelodysplastic syndromes.
Zeidan AM; Linhares Y; Gore SD
Blood Rev; 2013 Sep; 27(5):243-59. PubMed ID: 23954262
[TBL] [Abstract][Full Text] [Related]
2. Beyond hypomethylating agents failure in patients with myelodysplastic syndromes.
Zeidan AM; Kharfan-Dabaja MA; Komrokji RS
Curr Opin Hematol; 2014 Mar; 21(2):123-30. PubMed ID: 24335709
[TBL] [Abstract][Full Text] [Related]
3. Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years.
Feld J; Belasen A; Navada SC
Expert Rev Anticancer Ther; 2020 Jun; 20(6):465-482. PubMed ID: 32479130
[TBL] [Abstract][Full Text] [Related]
4. Hypomethylating agents and other novel strategies in myelodysplastic syndromes.
Garcia-Manero G; Fenaux P
J Clin Oncol; 2011 Feb; 29(5):516-23. PubMed ID: 21220589
[TBL] [Abstract][Full Text] [Related]
5. New Approaches to Myelodysplastic Syndrome Treatment.
Bazinet A; Bravo GM
Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
[TBL] [Abstract][Full Text] [Related]
6. Management of myelodysplastic syndromes: 2008 update.
Scott BL; Estey E
Oncology (Williston Park); 2008 Nov; 22(12):1344-52. PubMed ID: 19086598
[TBL] [Abstract][Full Text] [Related]
7. Optimal sequencing of treatments for patients with myelodysplastic syndromes.
Itzykson R; Fenaux P
Curr Opin Hematol; 2009 Mar; 16(2):77-83. PubMed ID: 19468268
[TBL] [Abstract][Full Text] [Related]
8. High-risk myelodysplastic syndromes: chemotherapy, transplantation, and beyond.
Gergis U; Wissa U
Curr Hematol Malig Rep; 2010 Jan; 5(1):1-8. PubMed ID: 20425390
[TBL] [Abstract][Full Text] [Related]
9. Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
Festuccia M; Baker K; Gooley TA; Sandmaier BM; Deeg HJ; Scott BL
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1509-1514. PubMed ID: 28600031
[TBL] [Abstract][Full Text] [Related]
10. Update on the pharmacotherapy for myelodysplastic syndromes.
Duong VH; Komrokji RS; List AF
Expert Opin Pharmacother; 2014 Sep; 15(13):1811-25. PubMed ID: 25080144
[TBL] [Abstract][Full Text] [Related]
11. Treatment of MDS.
Platzbecker U
Blood; 2019 Mar; 133(10):1096-1107. PubMed ID: 30670446
[TBL] [Abstract][Full Text] [Related]
12. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
Garcia-Manero G
Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
[TBL] [Abstract][Full Text] [Related]
13. Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?
Steensma DP
Best Pract Res Clin Haematol; 2012 Dec; 25(4):443-51. PubMed ID: 23200541
[TBL] [Abstract][Full Text] [Related]
14. Novel therapies in low- and high-risk myelodysplastic syndrome.
Germing U; Schroeder T; Kaivers J; Kündgen A; Kobbe G; Gattermann N
Expert Rev Hematol; 2019 Oct; 12(10):893-908. PubMed ID: 31353975
[No Abstract] [Full Text] [Related]
15. Therapy-related myelodysplastic syndromes, or are they?
Abou Zahr A; Kavi AM; Mukherjee S; Zeidan AM
Blood Rev; 2017 May; 31(3):119-128. PubMed ID: 27923516
[TBL] [Abstract][Full Text] [Related]
16. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
Flotho C; Sommer S; Lübbert M
Semin Cancer Biol; 2018 Aug; 51():68-79. PubMed ID: 29129488
[TBL] [Abstract][Full Text] [Related]
17. How we treat higher-risk myelodysplastic syndromes.
Sekeres MA; Cutler C
Blood; 2014 Feb; 123(6):829-36. PubMed ID: 24363399
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of higher risk myelodysplastic syndromes].
Usuki K
Rinsho Ketsueki; 2019; 60(9):1131-1139. PubMed ID: 31597836
[TBL] [Abstract][Full Text] [Related]
19. Myelodysplastic syndromes current treatment algorithm 2018.
Steensma DP
Blood Cancer J; 2018 May; 8(5):47. PubMed ID: 29795386
[TBL] [Abstract][Full Text] [Related]
20. Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.
Kadia TM; Jabbour E; Kantarjian H
Semin Oncol; 2011 Oct; 38(5):682-92. PubMed ID: 21943675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]